Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Original) A compound according to the general Formula (I)



(I)

the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the *N*-oxide form thereof and prodrugs thereof, whereinn is an integer, equal to 0, 1 or 2 ;

m is an integer, equal to 1 or 2, provided that if m is 2, then n is 1 ;

p is an integer equal to 1 or 2 ;

q is an integer equal to 0 or 1 ;

Q is O or NR^3 ;

X is a covalent bond or a bivalent radical of formula -O-, -S- or $-NR^3-$;

each R^3 independently from each other, is hydrogen or alkyl ;

each R^1 independently from each other, is selected from the group of Ar^1, Ar^1-alkyl and di(Ar^1)-alkyl ;

R^2 is Ar^2, Ar^2-alkyl, di(Ar^2)alkyl, Het^1 or Het^1-alkyl ;

Y is a covalent bond or a bivalent radical of formula -C(=O)-,$-SO_2-$, >C=CH-R or >C=N-R, wherein R is CN or nitro ;

each Alk represents, independently from each other, a covalent bond ; a bivalent straight or branched,

saturated or unsaturated hydrocarbon radical having from 1 to 6 carbon atoms ; or a cyclic saturated or unsaturated hydrocarbon radical having from 3 to 6 carbon atoms ; each radical optionally substituted on one or more carbon atoms with one or more phenyl, halo, cyano, hydroxy, formyl and amino radicals ;

L is selected from the group of hydrogen, alkyl, alkyloxy, Ar^3-oxy, alkyloxycarbonyl, alkylcarbonyloxy, mono- and di(alkyl)amino, mono- and di(Ar^3)amino, Ar^3, Ar^3carbonyl, Het^2 and Het^2carbonyl ;

Ar^1 is phenyl, optionally substituted with 1, 2 or 3 substituents, each independently from each other, selected from the group of halo, alkyl, cyano, aminocarbonyl and alkyloxy ;

Ar^2 is naphthalenyl or phenyl, each optionally substituted with 1, 2 or 3 substituents, each independently from each other, selected from the group of halo, nitro, amino, mono- and di(alkyl)amino, cyano, alkyl, hydroxy, alkyloxy, carboxyl, alkyloxycarbonyl, aminocarbonyl and mono- and di(alkyl)aminocarbonyl ;

Ar^3 is naphthalenyl or phenyl, optionally substituted with 1, 2 or 3 substituents, each independently from each other, selected from the group of alkyloxy, alkyl, halo, hydroxy, Ar^1carbonyloxycarbonyl, pyridinyl, morpholinyl, pyrrolidinyl, imidazo[1,2-*a*]pyridinyl, morpholinylcarbonyl, pyrrolidinylcarbonyl, amino and cyano ;

Het^1 is a monocyclic heterocyclic radical selected from the the group of pyrrolyl, pyrazolyl, imidazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl ; or a bicyclic heterocyclic radical selected from the group of

quinolinyl, quinoxalinyl, indolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzofuranyl, benzothienyl and 4a,8a-dihydro-2*H*-chromenyl ; each heterocyclic radical may optionally be substituted on any atom by one or more radicals selected from the group of halo, oxo and alkyl ;

Het^2 is a monocyclic heterocyclic radical selected from the group of tetrahydrofuranyl, pyrrolidinyl, dioxolyl, imidazolidinyl, pyrrazolidinyl, piperidinyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl, imidazolidinyl, tetrahydrofuranyl, 2H-pyrrolyl, pyrrolinyl, imidazolinyl, pyrrazolinyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl and triazinyl ;

or a bicyclic heterocyclic radical selected from the group of benzopiperidinyl, quinolinyl, quinoxalinyl, indolyl, isoindolyl, chromenyl, benzimidazolyl, imidazo[1,2-*a*]pyridinyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzofuranyl, benzothienyl, benzo [2,1,3]oxadiazolyl, imidazo[2,1-b]thiazolyl , 2,3-dihydrobenzo[1,4]dioxyl and octahydrobenzo-[1,4]dioxyl ;

each radical may optionally be substituted with one or more radicals selected from the group of Ar^1, Ar^1alkyl, Ar^1alkyloxyalkyl, halo, hydroxy, alkyl, alkylcarbonyl, alkyloxy, alkyloxyalkyl, alkyloxycarbonyl, piperidinyl, pyridinyl, pyrrolyl, thienyl, oxo and oxazolyl ; and

alkyl is a straight or branched saturated hydrocarbon radical having with one or more radicals selected from the group of phenyl, halo, cyano, oxo, hydroxy, formyl and amino.

2. (Original) A compound according to claim 1, characterized in that

n is 1 ;

m is 1 ;

p is 1 ;

q is 0 ;

Q is O ;

X is a covalent bond ;

each R^1 is Ar^1 or Ar^1-alkyl ;

R^2 is Ar^2 ;

Y is a covalent bond or a bivalent radical of formula -C(=O)-, $-SO_2-$ or >C=CH-R or >C=N-R, wherein R is CN or nitro ;

each Alk represents, independently from each other, a covalent bond ; a bivalent straight or branched, saturated hydrocarbon radical having from 1 to 6 carbon atoms ; or a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms ; each radical optionally substituted on one or more carbon atoms with one or more hydroxy radicals ;

L is selected from the group of hydrogen, alkyl, alkyloxy, alkylcarbonyloxy, mono- and di(alkyl)amino, mono-and di(Ar^3)amino, Ar^3, Het^2 and Het^2carbonyl ;

Ar^1 is phenyl ;

Ar^2 is phenyl, optionally substituted with 1, 2 or 3 alkyl radicals ;

Ar^3 is phenyl, optionally substituted with 1, 2 or 3 substituents, each independently from each other, selected from the group of alkyloxy, alkyl, halo, hydroxy, Ar^1carbonyloxycarbonyl and cyano;

Het^2 is a heterocyclic radical selected from the group of tetrahydrofuranyl, pyrrolidinyl, imidazolyl, pyrazolyl, furanyl, thienyl, isoxazolyl, thiazolyl, thiadiazolyl, pyridinyl,

pyrazinyl, benzo [2,1,3]oxadiazolyl and imidazo[2,1-b]thiazolyl ; each radical optionally substituted with one or more Ar^1alkyloxyalkyl, halo, alkyl, alkylcarbonyl, pyridinyl or oxazolyl radicals ; and

alkyl is a straight hydrocarbon radical having 1 to 6 carbon atoms, optionally substituted with one or more radicals selected from the group of halo and hydroxy~~;~~.

3. (Currently Amended) A compound according to Claim 1 ~~any of claims 1-2, characterized in that~~ wherein R^1 is Ar^1methyl and attached to the 2-position or R^1 is Ar^1 and attached to the 3-position .

4. (Currently Amended)A compound according to Claim 1 ~~any of claims 1-3, characterized in that~~ wherein the R^2-X-C(=Q)- moiety is 3,5-di-(trifluoromethyl) phenylcarbonyl.

5. (Currently Amended) A compound according to Claim 1 ~~any of claims 1-4, characterized in that~~ wherein p is 1.

6. (Currently Amended) A compound according to Claim 1 ~~any of claims 1-5, characterized in that~~ wherein Y is -C(=O)-.

7. (Currently Amended) A compound according to Claim 1 ~~any of claims 1-6, characterized in that~~ wherein Alk is a covalent bond.

8. (Currently Amended) A compound according to Claim 1 ~~any of claims 1-3, characterized in that~~ wherein L is Het^2.

9. (Currently Amended) A compound selected from the

group of compounds with compound number 25, 48, 79, 39, 15, 41, 64, 88, 50, 59 and 3, as ~~mentioned~~ described in any one of Tables 1-2.

10. (Currently Amended) A compound according to Claim 1 ~~any one of claims 1-9~~ for use as a medicine.

11. (Currently Amended) The use of a compound according to ~~any one of claims 1-10~~ Claim 1 ~~for the manufacture of a medicament for~~ treating tachykinin mediated conditions.

12. (Currently Amended) The use of a compound according to claim 11 for ~~the manufacture of a medicament for~~ treating schizophrenia, emesis, anxiety, depression, irritable bowel syndrome (IBS), circadian rhythm disturbances, pain, neurogenic inflammation, asthma, micturition disorders ~~such as urinary incontinence~~ and nociception.

13. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound according to ~~any one of claims 1-9~~ Claim 1.

14. (Currently Amended) A process for preparing a pharmaceutical composition as claimed in claim 13, ~~characterized in that~~ wherein a pharmaceutically acceptable carrier is intimately mixed with a therapeutically effective amount of a compound as claimed in ~~any one of claims 1-9~~ Claim 1.

15. (Original) A process for the preparation of a compound of Formula (I'') in which an intermediate compound of Formula (II) is reacted with an intermediate compound of Formula (III), wherein the

radicals R^2, X, Q, R^1, m, n, p and q are as defined in claim 1.



(II) (III)

(I'')

16. (Original) A process for the preparation of a compound of Formula (I') in which a final compound of Formula (I'') is reductively hydrogenated, wherein the radicals R^2, X, Q, R^1, m, n, p and q are as defined in claim 1.



(I'') (I')

17. (Original) A process for the preparation of a compound according to Formula (I') comprising the consecutive steps of

1) obtaining a compound of Formula (I'') according to claim 15 ;

2) obtaining a compound of Formula (I') according to claim 16.